Combining Inhibitors of the DNA Damage Response Pathway with Immunotherapies to Treat Cancer
Time: 11:15 am
day: Day One
Details:
- The multiple interfaces between the DDR and the immune response
- PARP inhibitor immune priming in BRCA deficient cancers
- The link between ATR inhibition, replication stress and the ability to overcome immunotherapy resistance